250 related articles for article (PubMed ID: 34086347)
1. Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood.
Ting MA; Reuther J; Chandramohan R; Voicu H; Gandhi I; Liu M; Cortes-Santiago N; Foster JH; Hicks J; Nuchtern J; Scollon S; Plon SE; Chintagumpala M; Rainusso N; Roy A; Parsons DW
J Pathol; 2021 Sep; 255(1):52-61. PubMed ID: 34086347
[TBL] [Abstract][Full Text] [Related]
2. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Rekhi B; Upadhyay P; Ramteke MP; Dutt A
Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
[TBL] [Abstract][Full Text] [Related]
3. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
[TBL] [Abstract][Full Text] [Related]
4. Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis.
Agaram NP; Chen CL; Zhang L; LaQuaglia MP; Wexler L; Antonescu CR
Genes Chromosomes Cancer; 2014 Sep; 53(9):779-87. PubMed ID: 24824843
[TBL] [Abstract][Full Text] [Related]
5. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.
Agaram NP; LaQuaglia MP; Alaggio R; Zhang L; Fujisawa Y; Ladanyi M; Wexler LH; Antonescu CR
Mod Pathol; 2019 Jan; 32(1):27-36. PubMed ID: 30181563
[TBL] [Abstract][Full Text] [Related]
6. Functional impact and targetability of
Choo F; Odintsov I; Nusser K; Nicholson KS; Davis L; Corless CL; Stork L; Somwar R; Ladanyi M; Davis JL; Davare MA
Cold Spring Harb Mol Case Stud; 2022 Jan; 8(1):. PubMed ID: 35012940
[TBL] [Abstract][Full Text] [Related]
7. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma.
Szuhai K; de Jong D; Leung WY; Fletcher CD; Hogendoorn PC
J Pathol; 2014 Feb; 232(3):300-7. PubMed ID: 24272621
[TBL] [Abstract][Full Text] [Related]
8. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
Rekhi B; Dodd L; Dharavath B; Dutt A
Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and Molecular Study of an Adult Sclerosing Rhabdomyosarcoma of the Extremity:
Gorunova L; Bjerkehagen B; Micci F; Heim S; Panagopoulos I
Cancer Genomics Proteomics; 2020; 17(5):563-569. PubMed ID: 32859634
[TBL] [Abstract][Full Text] [Related]
10. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases].
Yang L; Zhang HJ; Yang SJ
Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670
[No Abstract] [Full Text] [Related]
11. Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile.
Schleicher S; Grote S; Malenke E; Chan KC; Schaller M; Fehrenbacher B; Riester R; Kluba T; Frauenfeld L; Boesmueller H; Göhring G; Schlegelberger B; Handgretinger R; Kopp HG; Traub F; Boehme KA
Cells; 2020 Dec; 9(12):. PubMed ID: 33322555
[TBL] [Abstract][Full Text] [Related]
12. Sclerosing rhabdomyosarcoma in childhood: case report and review of the literature.
Vadgama B; Sebire NJ; Malone M; Ramsay AD
Pediatr Dev Pathol; 2004; 7(4):391-6. PubMed ID: 15383934
[TBL] [Abstract][Full Text] [Related]
13. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
14. Evolving classification of rhabdomyosarcoma.
Agaram NP
Histopathology; 2022 Jan; 80(1):98-108. PubMed ID: 34958505
[TBL] [Abstract][Full Text] [Related]
15. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
Kohsaka S; Shukla N; Ameur N; Ito T; Ng CK; Wang L; Lim D; Marchetti A; Viale A; Pirun M; Socci ND; Qin LX; Sciot R; Bridge J; Singer S; Meyers P; Wexler LH; Barr FG; Dogan S; Fletcher JA; Reis-Filho JS; Ladanyi M
Nat Genet; 2014 Jun; 46(6):595-600. PubMed ID: 24793135
[TBL] [Abstract][Full Text] [Related]
16. MYOD1 as a prognostic indicator in rhabdomyosarcoma.
Ahmed AA; Habeebu S; Farooqi MS; Gamis AS; Gonzalez E; Flatt T; Sherman A; Surrey L; Arnold MA; Conces M; Koo S; Dioufa N; Barr FG; Tsokos MG
Pediatr Blood Cancer; 2021 Sep; 68(9):e29085. PubMed ID: 33913590
[TBL] [Abstract][Full Text] [Related]
17. Biological Role and Clinical Implications of
Di Carlo D; Chisholm J; Kelsey A; Alaggio R; Bisogno G; Minard-Colin V; Jenney M; Dávila Fajardo R; Merks JHM; Shipley JM; Selfe JL
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980529
[TBL] [Abstract][Full Text] [Related]
18. Update on Myogenic Sarcomas.
Agaram NP
Surg Pathol Clin; 2019 Mar; 12(1):51-62. PubMed ID: 30709448
[TBL] [Abstract][Full Text] [Related]
19. [Congenital spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological analysis].
Xu JT; Fu LB; Yao XF; Jia C; Guan XX; Zhang M; He LJ
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):344-350. PubMed ID: 38556817
[No Abstract] [Full Text] [Related]
20. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]